Cart
sales@molnova.com
Lirimilast
CAS No. 329306-27-6
Lirimilast ( BAY 19-8004;BAY 198004 )
Catalog No. M14085 CAS No. 329306-27-6
Lirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 419 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLirimilast
-
NoteResearch use only, not for human use.
-
Brief DescriptionLirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.
-
DescriptionLirimilast (BAY 19-8004;BAY 198004) is a potent and selective PDE4 inhibitor for the treatment of COPD.COPD Phase 2 Discontinued
-
SynonymsBAY 19-8004;BAY 198004
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research AreaInflammation/Immunology
-
IndicationCOPD
Chemical Information
-
CAS Number329306-27-6
-
Formula Weight443.25
-
Molecular FormulaC17H12Cl2N2O6S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCS(=O)(OC1=CC=C2C(NC(N)=O)=C(C(C3=CC=C(Cl)C=C3Cl)=O)OC2=C1)=O
-
Chemical Name[3-(carbamoylamino)-2-(2,4-dichlorobenzoyl)-1-benzofuran-6-yl] methanesulfonate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Grootendorst DC, et al. Pulm Pharmacol Ther. 2003;16(6):341-7.
molnova catalog
related products
-
Cilostazol
Cilostazol (OPC 13013, OPC 21) is a potent inhibitor of PDE3A with IC50 of 0.2 uM; inhibits platelet aggregation and has considerable antithrombotic effects in vivo.
-
Lotamilast
Lotamilast (RVT 501, E6005) is apotent, selective PDE4 inhibitor with IC50 of 2.8 nM, suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 of 0.49-3.1 nM.
-
Oglemilast
Oglemilast (GRC-3886) is a potent and selective PDE4 inhibitor with IC50 of 2.5 and 1.7 nM for PDE4B and PDE4D, respectively.
